HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Jeffrey M. Piehler Permission Requests Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Piehler, J. M. Search for Related Content PubMed Articles by Piehler, J. M. Related Collections Lung - cancer

Ann Thorac Surg 2004;78:1206
© 2004 The Society of Thoracic Surgeons

INVITED COMMENTARY

Department of Cardiothoracic Surgery, University of Kansas Medical Center3901 Rainbow Blvd, Kansas City, KS 66160, USA

The first 20% of the full text of this article appears below.

Acknowledgement of the limitations of current therapy for the large number of patients with locally advanced lung cancer is part of the daily lexicon of general thoracic surgeons. While waiting for the much needed quantum leap in systemic therapy, we must be satisfied with small increments in survival that can sometimes be achieved by careful manipulation of existing therapeutic modalities. Granted, the staggering prevalence of the disease allows even small advances to be impressively magnified in number of lives altered; nevertheless, such epidemiologic consequences are of limited consolation to the individual surgeon who continues to witness far more failures than successes with these patients, usually due to systemic progression of disease.

The trimodality strategy of concomitant chemotherapy and radiation therapy followed by resection is now generally accepted as the preferred approach to . . . [Full Text of this Article]